A Phase 1, 3-part Study Of Pf-05221304 In Healthy Adults: Part 1 - Randomized, Double-blind, Placebo-controlled Assessment Of Safety And Pharmacokinetics Of Single, Escalating, Oral Doses; Part 2 - Randomized, Double-blind, Placebo-controlled Assessment Of Safety And Pharmacokinetics Of Repeated, Escalating, Oral Doses; Conditional Part 3 - Effect Of Food On The Pharmacokinetics Of Pf-05221304
Latest Information Update: 27 Feb 2020
At a glance
- Drugs Clesacostat (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Pfizer
- 17 Feb 2020 Results published in the Clinical Pharmacology in Drug Development
- 14 Apr 2018 Results assessing safety, tolerability, pharmacokinetics and pharmacodynamics of PF-05221304 following single and multiple oral doses, presented at The International Liver Congress 2018.
- 06 Apr 2017 Status changed from recruiting to completed.